QLT maintained by Merrill at neutral

QLT Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating in light of Genentech's results of its Lucentis vs. QLT's Visudyne two-year study in which Lucentis proved to be superior in maintaining or improving vision in patients with age-related macular degeneration. The market for the use of off-label Avastin also is expected to erode, Merrill said. Shares of the Vancouver, B.C., biopharmaceutical company were up 4 cents, or 0.59%, at $6.78 on volume of 1,519,671 shares versus the three-month running average of 1,184,030 shares. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.